SPAG5 serves as a promising prognostic factor in HCC and functions as an oncogene via the CEP55-mediated PI3K/AKT pathway; thus, the miR-363-3p/SPAG5/CEP55 axis may represent a potential therapeutic target for HCC clinical intervention [27]. The gene discussed is CEP55; the disease is hepatocellular carcinoma.